Loading…
Integra LifeSciences Holdings Corporation is projected to rise to $23.23 by 2027, a +24% move from its current price of $18.79. IART is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $18.30 | $18.79 | $19.30 | 0.00% |
| Jul 15 | $18.09 | $18.79 | $19.51 | 0.00% |
| Jul 16 | $17.94 | $18.79 | $19.68 | -0.01% |
| Jul 17 | $17.81 | $18.79 | $19.82 | -0.01% |
| Jul 18 | $17.70 | $18.79 | $19.94 | -0.01% |
| Jul 19 | $17.60 | $18.79 | $20.06 | -0.01% |
| Jul 20 | $17.51 | $18.79 | $20.16 | -0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.51 | $18.79 | $20.16 | -0.01% |
| Week 2 | $17.00 | $18.78 | $20.76 | -0.03% |
| Week 3 | $16.62 | $18.78 | $21.22 | -0.04% |
| Week 4 | $16.31 | $18.78 | $21.62 | -0.06% |
| Week 5 | $16.04 | $18.78 | $21.98 | -0.07% |
| Week 6 | $15.79 | $18.77 | $22.31 | -0.09% |
| Week 7 | $15.57 | $18.77 | $22.62 | -0.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.
The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair.
Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products.
Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. It was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995.
Integra LifeSciences Holdings Corporation, ticker IART, operates in the Healthcare sector. Current price is $18.79 with a market cap of $1.46B and a market-rank of 2263.
The stock trades with a 50-day simple moving average of $15.94 and a 200-day simple moving average of $12.98, with a near-term support at $15.67 and resistance at $18.79. The 30-day range spans from $15.76 to $22.40. Annualized volatility stands around 50%.
Longer-term forecasts show substantial upside across years, with the 2026 average price at $18.79 and an improving trajectory through 2050, including a 2030 average of $44.48 and a 2050 average of $304.00, accompanied by rising ROI figures spanning from 0 in 2026 to 136.7 (2030) and 1517.9 (2050).
A major floor 52.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 11.1% above — clearing it would confirm fresh momentum.
Key IART support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IART market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.02 | Buy | $18.22 | Buy |
| MA 10 | $18.15 | Buy | $18.07 | Buy |
| MA 20 | $17.90 | Buy | $17.70 | Buy |
| MA 50 | $15.94 | Buy | $16.08 | Buy |
| MA 100 | $13.07 | Buy | $14.52 | Buy |
| MA 200 | $12.98 | Buy | $14.09 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.83 | Neutral |
| Stoch RSI (14) | 62.58 | Neutral |
| CCI (20) | 156.76 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | 6.22 | Buy |
| Bollinger %B (20,2) | 0.98 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.65 | Buy |
| Awesome (5,34) | 0.82 | Buy |
| Ultimate (7,14,28) | 64.07 | Neutral |
| Momentum (10) | 0.69 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 18.01 | Buy |
| ADX (14) | 27.43 | Buy |
| ATR (14) | 0.41 | Info |
The 30-day technical picture is leaning bullish. RSI(14) sits at 60, with a constructive stance as price sits above the SMA50 of $15.94 and above the SMA200 of $12.98. Key near-term levels include support at $15.67 and resistance at $18.79.
The 30-day price range runs from $15.76 to $22.40, indicating room for upside and downside within a relatively tight band over the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.90 | $18.79 | $25.45 | 0% | Neutral | |
| $18.54 | $23.23 | $30.78 | +24% | Bullish | |
| $22.66 | $29.18 | $40.09 | +55% | Bullish | |
| $26.64 | $35.09 | $49.59 | +87% | Bullish | |
| $33.05 | $44.41 | $64.28 | +136% | Bullish | |
| $39.04 | $53.41 | $78.93 | +184% | Bullish | |
| $38.47 | $53.53 | $80.60 | +185% | Bullish | |
| $41.92 | $59.26 | $90.76 | +215% | Bullish | |
| $47.23 | $67.76 | $105.41 | +261% | Bullish | |
| $52.99 | $77.13 | $121.73 | +310% | Bullish | |
| $78.56 | $122.02 | $204.63 | +549% | Bullish | |
| $175.03 | $303.93 | $556.89 | +15.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.90 | $18.79 | $22.74 | +0.00% |
| August 2026 | $15.99 | $18.85 | $22.83 | +0.34% |
| September 2026 | $15.79 | $18.75 | $22.95 | -0.53% |
| October 2026 | $16.40 | $19.59 | $24.20 | +4.48% |
| November 2026 | $16.86 | $20.24 | $25.20 | +3.31% |
| December 2026 | $16.83 | $20.30 | $25.45 | +0.28% |
Click any year to see its month-by-month IART forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IART price prediction for 2026 points to an average of $18.79 (low $8.90, high $25.45) — a potential gain of 0% on today's $18.79. A consolidation phase looks the most probable path here.
In 2027, IART is projected to trade between $18.54 and $30.78, averaging $23.23 — a potential gain of +24% from today's $18.79. That is up +24% on the projected 2026 average. Momentum favours further upside here.
Integra LifeSciences Holdings Corporation's 2028 outlook centres on $29.18, within a $22.66 to $40.09 range. That is up +26% on the projected 2027 average. That marks a +55% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, IART could reach as high as $49.59, with a base case around $35.09 and support toward $26.64 — roughly +87% from $18.79. Momentum favours further upside here.
Expect IART to range from $33.05 to $64.28 through 2030. The $44.41 average target implies a +136% move from current prices. That is up +27% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IART price prediction for 2031 points to an average of $53.41 (low $39.04, high $78.93) — a potential gain of +184% on today's $18.79. Momentum favours further upside here.
In 2032, IART is projected to trade between $38.47 and $80.60, averaging $53.53 — a potential gain of +185% from today's $18.79. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Integra LifeSciences Holdings Corporation's 2033 outlook centres on $59.26, within a $41.92 to $90.76 range. That is up +11% on the projected 2032 average. That marks a +215% change versus current levels. Momentum favours further upside here.
By 2034, IART could reach as high as $105.41, with a base case around $67.76 and support toward $47.23 — roughly +261% from $18.79. Buyers look set to stay in control over this stretch.
Expect IART to range from $52.99 to $121.73 through 2035. The $77.13 average target implies a +310% move from current prices. That is up +14% on the projected 2034 average. Momentum favours further upside here.
The IART price prediction for 2040 points to an average of $122.02 (low $78.56, high $204.63) — a potential gain of +549% on today's $18.79. Buyers look set to stay in control over this stretch.
In 2050, IART is projected to trade between $175.03 and $556.89, averaging $303.93 — a potential gain of +15.2x from today's $18.79. That is up +149% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IART today (≈ 53.219798 IART) could be worth
$16,175.29
+$15,175.29 (+1518%) by 2050 · US Dollar
Based on the average projected IART price of $303.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IARTwould be worth at today's price.
$1,000 invested in IART on Jul 10, 2025 (≈ 75.930144 IART) would be worth
$1,426.73
+$426.73 (+42.7%) today · 1.43× · US Dollar
Based on a IART entry price of $13.17 vs. today's $18.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.05 | $1,041 | +4.1% |
| 1 month ago | $17.09 | $1,099.47 | +9.9% |
| 3 months ago | $9.9 | $1,897.98 | +89.8% |
| 6 months ago | $13.15 | $1,428.9 | +42.9% |
| 1 year ago | $13.17 | $1,426.73 | +42.7% |
| All time (5.0y) ago | $67.76 | $277.3 | -72.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IART forecast.
Our base-case forecast reaches $38.00 around 2030.
Implied market cap at $38.00: $2.96B
The multi-year forecast shows a bullish trajectory across the horizon, with 2026 starting at a avg of $18.79 and a max of $25.46 and a neutral sentiment. From 2027 onward, the outlook turns bullish with steadily higher averages: 2027 avg $23.27 (ROI 23.8), 2028 avg $29.18 (ROI 55.3), 2029 avg $35.10 (ROI 86.8), and 2030 avg $44.48 (ROI 136.7). The path continues to 2031–2035 with rising averages (e.g., 2031 avg $53.41, 2032 avg $53.49, 2033 avg $59.32, 2034 avg $67.80, 2035 avg $77.12) and then to 2040 avg $121.95 (ROI 549) and 2050 avg $304.00 (ROI 1517.9).
The max foreseen values rise accordingly (e.g., 2035 max $121.72, 2040 max $204.51, 2050 max $557.03). Overall, the forecast depicts strong upside potential with bullish sentiment in later years, tempered by notable volatility (annualized volatility about 50%).
Tap a question to reveal the answer.
2030 avg $44.48; min $33.10; max $64.38; ROI 136.7; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROI. 2030 avg $44.48 (ROI 136.7); 2040 avg $121.95 (ROI 549); 2050 avg $304.00 (ROI 1517.9). 2026 is Neutral.
Yes—the max forecasts exceed $100: 2035 max $121.72; 2040 max $204.51; 2050 max $557.03.
Current price $18.79; Market cap $1.46B.
30-day range low $15.76; high $22.40. Support is $15.67 and resistance is $18.79.
Integra LifeSciences Holdings Corporation Community Discussion
0Share your Integra LifeSciences Holdings Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.